More than two years into the COVID-19 pandemic, the world has witnessed the immense value of biopharmaceutical innovation. With numerous safe and effective vaccines and treatments developed in record time, PhRMA member companies are facilitating an unprecedented response to the pandemic. It took years of investment, collaboration across companies and borders, and the right public policies to encourage the risk-taking and research and development necessary to deliver the new treatments and vaccines.
